Clinical Scorecard: Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

At a Glance

Key Highlights

• Quadruplet therapy is now a Category 1 recommendation for transplant-ineligible patients.
• Significant improvement in overall survival from approximately 3 years to over 8-10 years.
• The IMROZ trial established quadruplet therapy as a new benchmark for transplant-ineligible patients.

Guideline-Based Recommendations

Diagnosis

• Active MM defined by IMWG criteria: ≥ 10% clonal plasma cells or biopsy-proven plasmacytoma with myeloma-defining events.

Management

• Quadruplet regimens (e.g., daratumumab or isatuximab with lenalidomide, bortezomib, and dexamethasone) are preferred.

Monitoring & Follow-up

• Assess minimal residual disease (MRD) negativity and progression-free survival (PFS).

Risks

• Consider comorbidities such as renal impairment, diabetes, and cardiovascular disease in treatment planning.

Patient & Prescribing Data

Older, frail, or medically complex patients, with approximately 40% aged 75 years or older.

Increased treatment intensity from doublet to triplet and quadruplet regimens improves outcomes.

Clinical Best Practices

• Utilize frailty assessments to guide treatment decisions.
• Monitor for treatment tolerability in older adults.

References

• NCCN Guidelines 2025
• Kaplan, 2022
• Usmani et al., 2025
• Manier et al., 2025